NCT03513484View on ClinicalTrials.gov

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 14, 2018

Primary Completion Date

December 11, 2023

Study Completion Date

January 31, 2027

Conditions
Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2AFibroblast Growth Factor Basic Form MeasurementFLT3 Internal Tandem DuplicationRecurrent Adult Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine

Given IV or SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nintedanib

Given PO

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Robert H. Lurie Cancer Center

OTHER

collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER